FITZWILLIAM COURT, 1ST FLOOR, DUBLIN 2, L2
Iterum Therapeutics Announces $20 Million At-the-Market Offering
Shareholder votes
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
Reports Second Quarter 2025 Financial Results
Entry into a Material Definitive Agreement
Other Events
Material Contracts
Q2
FY 2023
Q3
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence
Free Writing Prospectus